Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mycophenolate Mofetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 known ✓ | P12268 | 19/20 | 0.70 |
| ▸ | IMPDH1 known ✓ | P20839 | 14/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mycophenolate Mofetil SCHEMBL28390 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL218782 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29645056 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL10262894 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL4195 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL23581135 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL29571382 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL1235420 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL2257852 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 | |
| Mycophenolate Mofetil SCHEMBL3016437 | 0.99 | ALDH1A1 (0.98) | ALDH1A1LMNAHPGDABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4087577-B1 | TREATMENT OF MEMBRANOUS NEPHROPATHY, IGG4-RELATED DISEASE, AND ANTIPHOSPHOLIPID SYNDROME USING BTK INHIBITOR 2-[(3R)-3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3571298-B1 | TREATMENT OF KRABBE DISEASE WITH UMBILICAL CORD BLOOD TRANSPLANTION (UCBT) AND INCREASED GALACTOCEREBROSIDASE (GALC) EXPRESSION | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | claimed |
| EP-3463225-B1 | NINTEDANIB FOR REDUCING SCAR FORMATION AT THE SITE OF GLAUCOMA FILTRATION SURGERY | ADS THERAPEUTICS LLC (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4244375-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-12-17 | — | — | EP | claimed |
| EP-3893890-B1 | GINSENOSIDE M1 FOR USE IN THE TREATMENT OF DAMAGES IN ORGANS OR TISSUES IN A SUBJECT CAUSED BY INFECTION WITH CORONAVIRUS | LEE SHEAU LONG (TW) | 2025-12-10 | — | — | EP | claimed |
| EP-4321220-B1 | A1AT FOR TREATING ACUTE GRAFT VERSUS HOST DISEASE AFTER HEMATOPOEITIC CELL TRANSPLANTATION | CSL BEHRING LLC (US) | 2025-10-29 | — | — | EP | claimed |
| EP-3689371-B1 | PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF | AMGEN INC (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4152004-B9 | ASSAY FOR JC VIRUS ANTIBODIES | BIOGEN MA INC (US) | 2025-04-09 | — | — | EP | claimed |
| EP-3339865-B9 | ASSAY FOR JC VIRUS ANTIBODIES | BIOGEN MA INC (US) | 2022-12-14 | — | — | EP | claimed |
| EP-3575792-B1 | METHOD OF ASSESSING RISK OF PML | BIOGEN MA INC (US) | 2022-11-30 | — | — | EP | claimed |
| US-20220365083-A1 | METHOD FOR DETECTING LUPUS NEPHRITIS | RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) | 2022-11-17 | — | — | US | claimed |
| EP-3625368-B1 | METHODS FOR ASSESSING THE RISK OF DEVELOPING PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY CAUSED BY JOHN CUNNINGHAM VIRUS BY GENETIC TESTING | PML SCREENING LLC (US) | 2022-11-09 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-2640393-B1 | CBP/CATENIN ANTAGONISTS FOR ENHANCING ASYMMETRIC DIVISION OF SOMATIC STEM CELLS | UNIV SOUTHERN CALIFORNIA (US) | 2022-10-12 | — | — | EP | claimed |
| EP-3339865-B1 | ASSAY FOR JC VIRUS ANTIBODIES | BIOGEN MA INC (US) | 2022-08-24 | — | — | EP | claimed |
| EP-4042159-A1 | METHOD FOR DETECTING LUPUS NEPHRITIS | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) | 2022-08-17 | — | — | EP | claimed |
| EP-3502138-B9 | SILENT FC VARIANTS OF ANTI-CD40 ANTIBODIES | NOVARTIS AG (CH) | 2022-03-09 | — | — | EP | claimed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |